Abstract:Abstract Background Cannabis may be a substitute for opioids but previous studies have found conflicting results when using data from more recent years. Most studies have examined the relationship using state-level data, missing important sub-state variation in cannabis access. Objective To examine cannabis legalization on opioid use at the county level, using Colorado as a case study. Colorado allowed recreational cannabis stores in January 2014. Local communities could decide whether to allow dispensaries, creating variation in the level of exposure to cannabis outlets. Design Observational, quasi-experimental design exploiting county-level variation in allowance of recreational dispensaries. Subjects Colorado residents Measures We use licensing information from the Colorado Department of Revenue to measure county-level exposure to cannabis outlets. We use the state’s Prescription Drug Monitoring Program (2013–2018) to construct opioid-prescribing measures of number of 30-day fills and total morphine equivalents, both per county resident per quarter. We construct outcomes of opioid-related inpatient visits (2011–2018) and emergency department visits (2013–2018) with Colorado Hospital Association data. We use linear models in a differences-in-differences framework that accounts for the varying exposure to medical and recreational cannabis over time. There are 2048 county-quarter observations used in the analysis. Results We find mixed evidence of cannabis exposure on opioid-related outcomes at the county level. We find increasing exposure to recreational cannabis is associated with a statistically significant decrease in number of 30-day fills (coefficient: −117.6, p -value<0.01) and inpatient visits (coefficient: −0.8, p -value: 0.03), but not total MME nor ED visits. Counties with no medical exposure prior to recreational legalization experience greater reductions in the number of 30-day fills and MME than counties with prior medical exposure ( p =0.02 for both). Conclusions Our mixed findings suggest that further increases in cannabis beyond medical access may not always reduce opioid prescribing or opioid-related hospital visits at a population level.

Shared Control Individuals in Health Policy Evaluations with Application to Medical Cannabis Laws

Understanding Difference-in-differences methods to evaluate policy effects with staggered adoption: an application to Medicaid and HIV

Methodological considerations for estimating policy effects in the context of co-occurring policies

Measuring the Impact of Medical Cannabis Law Adoption on Employer-Sponsored Health Insurance Costs: A Difference-in-Difference Analysis, 2003-2022

A multistate approach for mediation analysis in the presence of semi-competing risks with application in cancer survival disparities

The addition of cannabis to prescription drug monitoring programs and medication fills in Medicaid

Identifying Optimal Methods for Addressing Confounding Bias When Estimating the Effects of State-Level Policies

Methods used to Account for Concurrent Analgesic Use in Randomized Controlled Trials of Interventional Pain Treatments: A Meta-Epidemiologic Study

Evaluating the Health Impact of Large-Scale Public Policy Changes: Classical and Novel Approaches

Methodology for Evaluating a Partially Controlled Longitudinal Treatment Using Principal Stratification, With Application to a Needle Exchange Program

Estimating restricted mean treatment effects with stacked survival models

A Matched Design for Causal Inference With Survey Data: Evaluation of Medical Marijuana Legalization in Kentucky and Tennessee

Painful Subjects, Desiring Relief: Experiencing and Governing Pain in a Medical Cannabis Program

The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare

Disparities in access but not outcomes: Medicaid versus non-Medicaid patients in multidisciplinary chronic pain rehabilitation

Addressing Confusion and Inconsistencies Surrounding the Provider Role in Medical Cannabis Programs

Associations between cannabis policies and state-level specialty cannabis use disorder treatment in the United States, 2004-2019

Impact of Recreational Cannabis Legalization on Opioid Prescribing and Opioid-Related Hospital Visits in Colorado: an Observational Study

Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application

Synthetic controls with staggered adoption

Environmental Justice Implications of Power Plant Emissions Control Policies: Heterogeneous Causal Effect Estimation under Bipartite Network Interference